BioCentury
ARTICLE | Clinical News

ESP-01: Phase Ib/IIa started

May 2, 2016 7:00 AM UTC

Esperas began an open-label, Canadian Phase Ib/IIa trial to evaluate 10-200 mg oral ESP-01 given 3 or 5 days a week in 21-day cycles with or without gemcitabine in about 93 patients with advanced or m...